HSD17B13 – Medxy AI

Skip to content

Specialties
Clinical Updates
Medical News
iDoctor

Specialties
Clinical Updates
Medical News
iDoctor

Search for:

facebook.com
twitter.com
t.me
instagram.com
youtube.com

Home
HSD17B13

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis

Posted inClinical Updates Diabetes & Endocrinology Internal Medicine news Specialties

Rapirosiran: A Promising RNA Interference Therapy Targeting HSD17B13 for Metabolic Dysfunction-Associated Steatohepatitis

Posted by

By MedXY 09/20/2025

This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

Posted inClinical Updates Gastroenterology Internal Medicine news

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

Posted by

By MedXY 09/20/2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Beyond the Common Cold: Deciphering the Surge of Influenza Subclade K Across Europe
FDA Approve Twice-Yearly Depemokimab for Severe Eosinophilic Asthma Management
High-Dose Extended-Release Buprenorphine: A Targeted Strategy for the Fentanyl-Driven Opioid Crisis
Academic vs. Industry: Why Non-Industry Trials Are Failing to Reach the Finish Line
Real-World Implementation of RTS,S/AS01E Malaria Vaccine Reduces Severe Malaria by 58%: Evidence from the EPI-MAL-003 Phase 4 Study

About us
Contact us
MedXY story
Privacy Policy
Subscribe Now!
账号

English
日本語
Tiếng Việt
中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening SGLT2 inhibitors targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.

Sign in